Mylan/Momenta announce development strategy for aflibercept biosimilar

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Mylan/Momenta announce development strategy for aflibercept biosimilar

Biosimilares/General | Posted 26/01/2018 0 Post your comment

US generics giant Mylan and partner Momenta Pharmaceuticals announced on 3 January 2017 their development strategy for their aflibercept biosimilar, M710.

The product is a proposed biosimilar of Regeneron’s wet age-related macular degeneration treatment, Eylea (aflibercept). Eylea is the market-leading vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy in patients with diabetic macular edema.

The companies’ plans for M710 include initiating a pivotal clinical trial in the first half of 2018. According to the joint press release, the trial will be a randomized, double-blind, active-control, multicentre study in patients with diabetic macular edema to compare the safety, efficacy and immunogenicity of M710 with Eylea.

Momenta is also developing M834, a proposed biosimilar to Orencia (abatacept) in collaboration with Mylan [1], and M923, a proposed biosimilar to Humira (adalimumab) [2].

Mylan is collaborating with Polish firm Mabion on a rituximab biosimilar (MabionCD20) [3]. The company is also collaborating with Indian firm Biocon on a pegfilgrastim biosimilar (MYL‑1401H) [4], a trastuzumab biosimilar (MYL‑1401O) [5], an insulin lispro biosimilar [6], and an insulin glargine biosimilar (MYL‑1501D) [7].

Mabion signs agreement with Mylan for rituximab biosimilar

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of abatacept [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-abatacept
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of adalimumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-adalimumab
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of rituximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab
4. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of pegfilgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-pegfilgrastim
5. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of trastuzumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumab
6. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of insulin lispro [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-insulin-lispro
7. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of insulin glargine [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-insulin-glargine

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Momenta, Mylan